KalVista Pharmaceuticals (KALV) Net Cash Flow Growth (5y) (2021 - 2025)
KalVista Pharmaceuticals (KALV) Net Cash Flow Growth (5y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -47.95% |
| Apr 30, 2025 | -72.04% |
| Oct 31, 2024 | 24.70% |
| Jul 31, 2024 | 47.14% |
| Apr 30, 2024 | 18.75% |
| Jan 31, 2024 | 12.27% |
| Oct 31, 2023 | -34.55% |
| Jul 31, 2023 | -30.46% |
| Apr 30, 2023 | -32.57% |
| Jan 31, 2023 | 10.45% |
| Oct 31, 2022 | 46.25% |
| Jul 31, 2022 | 29.48% |
| Apr 30, 2022 | -39.95% |
| Jan 31, 2022 | -15.07% |
| Oct 31, 2021 | 15.24% |
| Jul 31, 2021 | 16.99% |